|
|
|
|
|
|
|
|
|
|
medical news
"We wanted to explore anti-PD-L1 therapies specifically for ovarian cancer, but we also wanted to determine if other drugs that did not cause these negative anti-PD-L1 antibody-related side effects could be used to target this cancer-promoting pathway," said Rugang Zhang, Ph.D., professor and co-program leader in the Gene Expression and Regulation program at The Wistar Institute and lead author of the study.
More information: Cell Reports, DOI: 10.1016/j.celrep.2016.08.032
Journal reference: Cell Reports
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.